To buy shares in UroGen Pharma Ltd. you will need a US based stock trading platform like Interactive Brokers, eToro or Moomoo where it currently costs $19.45 to buy one share in UroGen Pharma Ltd. (as of 16:00 29-Aug-2025). Which is a change of $0.21 or 1.09% from the last closing price of $19.24.
How To Buy UroGen Pharma Ltd. Stock
It may seem complicated to buy stock for the first time, but it’s actually very easy. Follow these simple steps to buy shares in UroGen Pharma Ltd.:
- Pick a stock broker (jump down to compare the best brokers for buying UroGen Pharma Ltd. stock)
- Deposit funds (bank transfer, ACH, wire transfer, or card)
- Search for the stock symbol: (NASDAQ:URGN)
- Choose the number of shares you want to buy (1 share currently costs $19.45)
- Click buy (you can either trade immediately at “market” or set a “limit” to buy the stock cheaper if you think the price will go down)
- Track the performance of your UroGen Pharma Ltd. stock in your account (this will show your profit and loss)
- UroGen Pharma Ltd. is currently worth $913,868,010 based on the last closing price of $19.24 with 1,286,896 shares traded.
- The most recent UroGen Pharma Ltd. daily high has been $19.67 and daily low $18.75.
- The UroGen Pharma Ltd. stock price 52 week high has been $21.02 and the 52 week low $3.42.
Compare Brokers For Buying UroGen Pharma Ltd. Stock
Is Now A Good Time To Buy UroGen Pharma Ltd. Stock?
- UroGen Pharma Ltd.’s EPS (earnings per share) are -3.17. A high EPS indicates strong profitability but may already be priced in, while a low EPS could signal weak earnings or a turnaround opportunity, requiring industry comparison.
- UroGen Pharma Ltd.’s PE (price earnings ratio) is n/a. A low PE ratio may suggest undervaluation but could also indicate slow growth or risk, whereas a high PE ratio reflects high growth expectations but may signal overvaluation, necessitating a check on earnings sustainability.
The below UroGen Pharma Ltd. share price analysis and market data includes key financials, earnings estimates, peer performance, dividends, news and a company profile that will give you an indication as to whether this stock is a buy, sell or hold.